AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
clidinium 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| muscarinic receptors agonists/antagonists | 676 | 7020-55-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
a synthetic anticholinergic agent that has antispasmodic and antisecretory effect on the gastrointestinal tract
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK,TGFBR1 | 20 | |||
| kinase-selectivity-class | AXL,GRK2,PDK4 | 3 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA | ROCHE |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Apraxia | 62.01 | 30.18 | 12 | 1004 | 2250 | 90625181 |
| Disorientation | 54.68 | 30.18 | 20 | 996 | 44094 | 90583337 |
| Perseveration | 54.64 | 30.18 | 8 | 1008 | 277 | 90627154 |
| Hyperreflexia | 44.06 | 30.18 | 11 | 1005 | 6646 | 90620785 |
| Cognitive disorder | 39.47 | 30.18 | 18 | 998 | 69389 | 90558042 |
| Myoclonus | 36.55 | 30.18 | 12 | 1004 | 19156 | 90608275 |
| Cholecystitis chronic | 30.78 | 30.18 | 9 | 1007 | 9817 | 90617614 |
| Dementia | 30.21 | 30.18 | 11 | 1005 | 23850 | 90603581 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Apraxia | 61.22 | 31.02 | 12 | 835 | 3528 | 110584924 |
| Perseveration | 54.46 | 31.02 | 8 | 839 | 419 | 110588033 |
| Hyperreflexia | 44.36 | 31.02 | 11 | 836 | 9474 | 110578978 |
| Disorientation | 42.30 | 31.02 | 17 | 830 | 70654 | 110517798 |
| Cognitive disorder | 38.80 | 31.02 | 17 | 830 | 87494 | 110500958 |
| Myoclonus | 34.66 | 31.02 | 12 | 835 | 32986 | 110555466 |
| Cholecystitis chronic | 34.48 | 31.02 | 9 | 838 | 9491 | 110578961 |
| Dementia | 31.27 | 31.02 | 11 | 836 | 31662 | 110556790 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A03CA02 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS Synthetic anticholinergic agents in combination with psycholeptics |
| FDA PE | N0000008779 | Decreased Parasympathetic Acetylcholine Activity |
| FDA PE | N0000009022 | Digestive/GI System Activity Alteration |
| FDA PE | N0000009048 | GI Motility Alteration |
| FDA MoA | N0000175370 | Cholinergic Antagonists |
| FDA EPC | N0000175574 | Anticholinergic |
| CHEBI has role | CHEBI:38070 | anti-arrhythmia drug |
| CHEBI has role | CHEBI:50370 | parasympatholytic |
| CHEBI has role | CHEBI:53784 | antispasmodic drug |
| MeSH PA | D010276 | Parasympatholytics |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
Related Drugs by ATC class:
A03CA Synthetic anticholinergic agents in combination with psycholeptics 10 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Irritable bowel syndrome | indication | 10743008 | DOID:9778 |
| Enterocolitis | indication | 43752006 | |
| Brain damage | contraindication | 2470005 | |
| Tachyarrhythmia | contraindication | 6285003 | |
| Suicidal thoughts | contraindication | 6471006 | |
| Urinary tract obstruction | contraindication | 7163005 | DOID:5200 |
| Severe chronic ulcerative colitis | contraindication | 14311001 | |
| Disorder of lung | contraindication | 19829001 | DOID:850 |
| Glaucoma | contraindication | 23986001 | DOID:1686 |
| Alcohol intoxication | contraindication | 25702006 | |
| Shock | contraindication | 27942005 | |
| Toxic megacolon | contraindication | 28536002 | DOID:1770 |
| Atony of colon | contraindication | 29479008 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Depressive disorder | contraindication | 35489007 | |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Complete trisomy 21 syndrome | contraindication | 41040004 | DOID:14250 |
| Hyperactive behavior | contraindication | 44548000 | |
| Achalasia of esophagus | contraindication | 45564002 | DOID:9164 |
| Chronic heart failure | contraindication | 48447003 | |
| Paralytic ileus | contraindication | 55525008 | DOID:8442 |
| Peptic reflux disease | contraindication | 57643001 | |
| Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
| Drug AND/OR toxin-induced diarrhea | contraindication | 65979008 | |
| Substance abuse | contraindication | 66214007 | |
| Psychotic disorder | contraindication | 69322001 | |
| Sleep apnea | contraindication | 73430006 | DOID:0050847 |
| Spastic paralysis | contraindication | 78403003 | |
| Disturbance of salivary secretion | contraindication | 78948009 | |
| Hiatal hernia | contraindication | 84089009 | DOID:12642 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Hypoalbuminemia | contraindication | 119247004 | |
| Gastrointestinal obstruction | contraindication | 126765001 | |
| Autonomic dysreflexia | contraindication | 129618003 | |
| Bleeding | contraindication | 131148009 | |
| Myocardial dysfunction | contraindication | 233928007 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Bladder outflow obstruction | contraindication | 236645006 | |
| Pyloric obstruction | contraindication | 244815007 | |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Retention of urine | contraindication | 267064002 | |
| Drowsy | contraindication | 271782001 | |
| Pregnancy, function | contraindication | 289908002 | |
| Severe chronic obstructive pulmonary disease | contraindication | 313299006 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
| Gastric ulcer | contraindication | 397825006 | DOID:10808 |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Chronic lung disease | contraindication | 413839001 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Porphyria | contraindication | 418470004 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.67 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Muscarinic acetylcholine receptor M1 | GPCR | ANTAGONIST | CHEMBL | CHEMBL | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | ANTAGONIST | Ki | 9.60 | IUPHAR | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019682 | VUID |
| N0000179084 | NUI |
| D00716 | KEGG_DRUG |
| 3485-62-9 | SECONDARY_CAS_RN |
| 21232 | RXNORM |
| C0055877 | UMLSCUI |
| CHEBI:3743 | CHEBI |
| CHEMBL620 | ChEMBL_ID |
| CHEMBL1200950 | ChEMBL_ID |
| DB00771 | DRUGBANK_ID |
| C054940 | MESH_SUPPLEMENTAL_RECORD_UI |
| 2784 | PUBCHEM_CID |
| 366 | IUPHAR_LIGAND_ID |
| BO76JF850N | UNII |
| 3953 | MMSL |
| 4465 | MMSL |
| d00991 | MMSL |
| 001747 | NDDF |
| 004702 | NDDF |
| 387323005 | SNOMEDCT_US |
| 57853003 | SNOMEDCT_US |
| 87283008 | SNOMEDCT_US |
| 463 | INN_ID |
| 4018831 | VANDF |
| 4019682 | VANDF |
| BO76JF850N | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Librax | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0187-4100 | CAPSULE | 2.50 mg | ORAL | NDA | 16 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0276-0500 | CAPSULE | 2.50 mg | ORAL | ANDA | 19 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10135-622 | CAPSULE | 2.50 mg | ORAL | UNAPPROVED DRUG OTHER | 17 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 11534-197 | CAPSULE | 2.50 mg | ORAL | ANDA | 19 sections |
| CHLORDIAZEPOXIDE HCL AND CLIDINIUM BROMIDE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42571-381 | CAPSULE | 2.50 mg | ORAL | ANDA | 21 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42582-300 | CAPSULE | 2.50 mg | ORAL | UNAPPROVED DRUG OTHER | 18 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42582-301 | CAPSULE | 2.50 mg | ORAL | UNAPPROVED DRUG OTHER | 18 sections |
| Chlordiazepoxide hydrochloride and clidinium bromide | Human Prescription Drug Label | 2 | 46708-744 | CAPSULE | 2.50 mg | ORAL | ANDA | 24 sections |
| Chlordiazepoxide Hydrochloride/Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-0131 | CAPSULE | 2.50 mg | ORAL | Unapproved drug other | 19 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-1528 | CAPSULE | 2.50 mg | ORAL | NDA authorized generic | 18 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | Human Prescription Drug Label | 2 | 59651-524 | CAPSULE | 2.50 mg | ORAL | ANDA | 24 sections |
| chlordiazepoxide hydrochloride and clidinium bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 60219-1677 | CAPSULE | 2.50 mg | ORAL | ANDA | 18 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 60687-639 | CAPSULE | 2.50 mg | ORAL | ANDA | 24 sections |
| CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 62135-696 | CAPSULE | 2.50 mg | ORAL | ANDA | 14 sections |
| Chlordiazepoxide hydrochloride and clidinium bromide | Human Prescription Drug Label | 2 | 62332-744 | CAPSULE | 2.50 mg | ORAL | ANDA | 24 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 63629-2373 | CAPSULE | 2.50 mg | ORAL | ANDA | 19 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 63629-8859 | CAPSULE | 2.50 mg | ORAL | ANDA | 18 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | Human Prescription Drug Label | 2 | 67877-731 | CAPSULE | 2.50 mg | ORAL | ANDA | 23 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 68151-2500 | CAPSULE | 2.50 mg | ORAL | NDA authorized generic | 18 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 69189-0489 | CAPSULE | 2.50 mg | ORAL | NDA authorized generic | 18 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 70700-185 | CAPSULE | 2.50 1 | ORAL | ANDA | 18 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 71186-006 | CAPSULE, GELATIN COATED | 2.50 mg | ORAL | UNAPPROVED DRUG OTHER | 19 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 71335-2966 | CAPSULE | 2.50 mg | ORAL | ANDA | 19 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 71335-9764 | CAPSULE | 2.50 mg | ORAL | ANDA | 19 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 72162-1237 | CAPSULE | 2.50 mg | ORAL | ANDA | 19 sections |
| CHLORDIAZEPOXIDE HCL AND CLIDINIUM BROMIDE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 72162-2436 | CAPSULE | 2.50 mg | ORAL | ANDA | 21 sections |
| CHLORDIAZEPOXIDE HCL AND CLIDINIUM BROMIDE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 72162-2436 | CAPSULE | 2.50 mg | ORAL | ANDA | 21 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 75826-134 | CAPSULE | 2.50 mg | ORAL | ANDA | 20 sections |